Does Clostridioides difficile infection cause hemorrhagic cystitis in a patient who has recently completed ceftriaxone and now presents with hematuria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, C. difficile Does Not Cause Hemorrhagic Cystitis

C. difficile infection (CDI) causes gastrointestinal disease—specifically diarrhea and colitis—not urinary tract pathology like hemorrhagic cystitis. The hematuria in your patient who recently completed ceftriaxone is unrelated to C. difficile and requires evaluation for other causes.

Understanding C. difficile Pathophysiology

C. difficile is a toxin-mediated infection that affects the colon exclusively 1, 2. The organism produces toxins A and B that act as glucosyltransferases, disrupting colonocyte cytoskeleton and causing cell death 2. This mechanism results in:

  • Diarrhea (≥3 unformed stools in 24 hours)
  • Pseudomembranous colitis
  • Toxic megacolon in severe cases
  • Colonic wall thickening and inflammation 3

C. difficile is not invasive and does not affect organs outside the gastrointestinal tract 1. The pathogen remains localized to the intestinal lumen where it produces toxins that damage the colonic epithelium.

Clinical Manifestations of CDI

The recognized presentations of CDI include 4:

  • Mild to moderate diarrhea
  • Abdominal cramping and pain
  • Fever
  • Leukocytosis (often marked, >15,000/mm³)
  • Pseudomembranous colitis
  • Toxic megacolon
  • Colonic perforation (rare, severe cases)

Notably absent from all guidelines and literature: any urinary tract symptoms or hemorrhagic cystitis 1, 3, 5, 6.

The Ceftriaxone Connection

Your patient's recent ceftriaxone exposure creates two separate clinical considerations:

1. Risk for C. difficile Infection

Ceftriaxone is a well-established risk factor for CDI 2, 7. Third-generation cephalosporins are among the antibiotics with the greatest CDI risk 2. However, CDI would present with diarrhea, not hematuria 1, 4.

2. Potential Urinary Tract Issues from Ceftriaxone

The FDA label for ceftriaxone lists urinary tract complications including 8:

  • Urolithiasis (ceftriaxone-calcium precipitates)
  • Ureteral obstruction
  • Post-renal acute renal failure
  • Casts in urine
  • Hematuria (as a direct drug effect)

The One Exception: A Case Report Caveat

There is one isolated case report of emphysematous cystitis occurring in a patient with recurrent C. difficile infection 9. However, this represents:

  • Gas in the bladder wall (emphysematous cystitis), not hemorrhagic cystitis
  • A single case in a 78-year-old with severe pseudomembranous colitis
  • Likely a coincidental finding or secondary complication in a critically ill patient
  • Not a recognized manifestation of CDI

This case does not establish causation and should not change clinical practice.

What to Evaluate Instead

For hematuria after ceftriaxone, investigate:

  1. Ceftriaxone-related urolithiasis - Check renal ultrasound for precipitates 8
  2. Bacterial cystitis - Urinalysis and urine culture
  3. Hemorrhagic cystitis from other causes - Chemical exposure, radiation, viral infection (BK virus, adenovirus), malignancy 10
  4. Medication effects - Direct drug toxicity from ceftriaxone 8

If C. difficile Testing is Considered

Only test for CDI if the patient has diarrhea (≥3 unformed stools in 24 hours) 1, 5. Testing should never be performed:

  • In patients without diarrhea
  • As a "test of cure"
  • For isolated hematuria or urinary symptoms 1, 4

The presence of hematuria alone is not an indication for C. difficile testing.

References

Research

Influence of ceftriaxone on emergence of Clostridium difficile.

Antimicrobial agents and chemotherapy, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.